All the authors signed confidentiality disclosures with the sponsor regarding these data. The analysis protocol was approved by an unbiased ethics institutional or committee review board at each participating site. The protocol, like the statistical analysis program, is offered by NEJM.org. All of the authors attest to the fidelity of the study to the protocol. Procedures At baseline , patients were assigned randomly, in a 1:1 ratio, to receive briakinumab, administered subcutaneously at a dose of 200 mg at weeks 0 and 4 and 100 mg every four weeks from week 8 through week 48, or methotrexate, administered orally in a dose of 5 to 25 mg per week, plus folate, administered at a dose of 5 mg per week orally, from week 0 through week 51 .Alcohol and the elderly: good news, bad information and the missed diagnosis Alcohol offers potential benefits and problems for all ages. Just a little is beneficial; a complete great deal is harmful. Here is what happens, and steps to make a diagnosis that is often missed. Although the elderly are less likely than their young counterparts to take harmful or hazardous degrees of alcohol, those who perform may suffer alcohol-related health problems. Alcohol-related problems in older people are caused by drug interactions often; altered medication pharmacokinetics and alcohol metabolism and increased medication make use of in older people contribute to this. Many elderly topics with drinking problems are not diagnosed. Late onset large drinkers ought to be distinguished from those that started drinking early because they respond better to therapy.